ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ibuprofen

Also written as “ibuprofen”, “Intravenous ibuprofen” and “Ibuprofen/acetaminophen”.

Its studies are mostly in Pain · Pain, Postoperative · Osteoarthritis · Fever · Osteoarthritis, Knee, led by 36 companies.

Drug pageIbuprofen: every studyMany companies study it; this page follows only the 101 they lead. All 433 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 22, 2008101 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer150 open or runningphase 4since Aug 22, 2008Aug 22, 2008none ahead
Cumberland Pharmaceuticalsits history only90 open or runningphase 4since Apr 12, 2011Sep 22, 2005none ahead
Johnson & Johnsonits history only70 open or runningphase 4since Oct 14, 2005Oct 14, 2005none ahead
Boehringer Ingelheimits history only60 open or runningphase 3since Aug 22, 2013Jul 26, 2010none ahead
Dr. Reddy's Laboratoriesits history only60 open or runningphase 1since Jan 20, 2010Jan 20, 2010none ahead
Reckittits history only60 open or runningphase 3since Oct 26, 2010Oct 26, 2010none ahead
AFT Pharmaceuticalsits history only51 open or runningphase 3since Aug 16, 2011Apr 14, 2010Mar 2027phase 3 · NCT07225634
Strategic Science & Technologiesits history only40 open or runningphase 3since Oct 11, 2012Oct 11, 2012none ahead
Angelini Pharmaits history only30 open or runningphase 1since Jun 17, 2015Jun 17, 2015none ahead
GlaxoSmithKlineits history only30 open or runningphase 4since Mar 28, 2013Sep 5, 2006none ahead

Also a collaborator on its studies: Premier Research Group, Parexel, Aptuit, Cross Research, Pharma Consulting Group AB, Pivotal S.L. and AAIPharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Aug 22, 2008.

  1. May 29, 2009Phase 2 study in PainNCT00913627 · 196 enrolled · United States
  2. Sep 21, 2009Phase 1 study in Rhinitis, AllergicNCT01064726 · 18 enrolled · United States
  3. Dec 8, 2009Phase 3 study in InfectionsNCT01035346 · 16 enrolled · United States
  4. Dec 22, 2010Phase 3 study in PainNCT01266161 · 106 enrolled · United States
  5. May 6, 2011Phase 4 study in HealthyNCT01350596 · 24 enrolled · Brazil
  6. Nov 3, 2011Phase 4 study in HealthyNCT01466517 · 70 enrolled · Brazil
  7. Mar 19, 2012Phase 2 study in PainNCT01559259 · 394 enrolled · United States
  8. Sep 19, 2012Phase 3 study in AgnosiaNCT01789606 · 1,083 enrolled · United States
  9. Dec 5, 2012Phase 1 study in PainNCT01771822 · 50 enrolled · United States
  10. Nov 14, 2014Phase 3 study in Patient ComplianceNCT02294019 · 738 enrolled · United States
  11. Jan 7, 2016Phase 3 study in PainNCT02912650 · 568 enrolled · United States
  12. May 2, 2016Phase 3 study in FeverNCT02761980 · 290 enrolled · United States
  13. Aug 8, 2016Phase 3 study in PainNCT02863575 · 374 enrolled · United States
  14. Oct 25, 2018Phase 3 study in PainNCT03722238 · 613 enrolled · United States

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 15 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03722238Pain · United States3TerminatedOct 28, 2019613
NCT02863575Pain · United States3CompletedApr 6, 2018374
NCT02761980Fever · United States3CompletedDec 6, 2017290
NCT02912650Pain · United States3CompletedJun 2016568
NCT02294019Patient Compliance · United States3CompletedMay 2015738
NCT01771822Pain · United States1CompletedFeb 201350
NCT01789606Agnosia · United States3CompletedJun 3, 20131,083
NCT01559259Pain · United States2CompletedSep 13, 2012394
NCT01466517Healthy · Brazil4CompletedNov 201170
NCT01350596Healthy · Brazil4CompletedMay 201124
NCT01266161Pain · United States3CompletedMar 31, 2011106
NCT01035346Infections · United States3TerminatedMay 201116
NCT01064726Rhinitis, Allergic · United States1CompletedApr 201018
NCT00913627Pain · United States2CompletedAug 1, 2009196
NCT00740857Pain · United States4CompletedNov 2008211

How it is read

Names in the registry

  • “Ibuprofen”, 40 entries
  • “ibuprofen”, 10 entries
  • “Intravenous ibuprofen”, 5 entries
  • “Ibuprofen/acetaminophen”, 4 entries
  • “ibuprofen + caffeine”, 3 entries

Codes read as this program: SST0225.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.